Ultra fast-acting insulin analogue - Adocia

Drug Profile

Ultra fast-acting insulin analogue - Adocia

Alternative Names: BC 106 Insulin Lispro; BC 222 Insulin Lispro; BioChaperone Lispro; BioChaperone Lispro U100; BioChaperone Lispro U200; BioChaperone® insulin analogue; BioChaperone® insulin lispro; BioChaperone® Ultra Fast Lispro

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adocia
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Recombinant proteins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 06 Dec 2017 Top-line efficacy data from a phase I trial in Type 1 diabetes mellitus released by Adocia
  • 11 Sep 2017 Adverse events and pharmacokinetics data from a phase Ib trial in Type-1 diabetes mellitus presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
  • 01 Jun 2017 Adocia initiates enrolment in a phase II trial in for Type-1 diabetes mellitus in Germany (NCT03179332)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top